Predictive Oncology Inc
POAI1.010USD
+0.023+2.31%
Fechamento 09/19, 16:00（ET）Cotações atrasadas em 15 min
9.69MValor de mercado
PerdaP/L TTM
Mais detalhes de Predictive Oncology Inc Empresa
Predictive Oncology Inc. is a knowledge-driven company focused on applying artificial intelligence (AI) to support the development of cancer therapies. The Company operates through three segments: Pittsburgh, Birmingham, and Eagan. Pittsburgh segment provides services, which include the application of artificial intelligence (AI) using its proprietary biobank of 150,000 plus tumor samples. Pittsburgh segment also develops tumor-specific in vitro models for oncology drug discovery and research. Birmingham segment focuses on contract services and research for biopharmaceutical company clients and academic collaborators, focused on solubility improvements, stability studies, and protein production. Specifically, Birmingham provides optimized formulations for vaccines, antibodies, and other protein therapeutics. Eagan segment produces the STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal.
Informações da empresa
Código da empresaPOAI
Nome da EmpresaPredictive Oncology Inc
Data de listagemDec 18, 2009
CEOMr. Raymond F. Vennare
Número de funcionários23
Tipo de títulosOrdinary Share
Fim do ano fiscalDec 18
Endereço91 43Rd Street
CidadePITTSBURGH
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal15201
Telefone14124321500
Sitehttps://predictive-oncology.com/
Código da empresaPOAI
Data de listagemDec 18, 2009
CEOMr. Raymond F. Vennare
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Raymond F. Vennare
Mr. Raymond F. Vennare
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
132.08K
+1754.55%
Mr. Joshua Blacher
Mr. Joshua Blacher
Interim Chief Financial Officer
Interim Chief Financial Officer
97.00K
--
Dr. Nancy Chung-Welch, Ph.D.
Dr. Nancy Chung-Welch, Ph.D.
Independent Director
Independent Director
83.99K
+334.90%
Dr. Daniel E. (Dan) Handley, Ph.D.
Dr. Daniel E. (Dan) Handley, Ph.D.
Independent Director
Independent Director
81.70K
+380.07%
Dr. Veena Rao, Ph.D.
Dr. Veena Rao, Ph.D.
Independent Director
Independent Director
73.80K
+709.44%
Dr. Matthew J. Hawryluk, Ph.D.
Dr. Matthew J. Hawryluk, Ph.D.
Independent Director
Independent Director
--
--
Mr. Gregory S. St. Clair, Sr.
Mr. Gregory S. St. Clair, Sr.
Independent Director
Independent Director
--
--
Mr. Chuck (Charles) Nuzum, Sr.
Mr. Chuck (Charles) Nuzum, Sr.
Lead Independent Director
Lead Independent Director
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Raymond F. Vennare
Mr. Raymond F. Vennare
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
132.08K
+1754.55%
Mr. Joshua Blacher
Mr. Joshua Blacher
Interim Chief Financial Officer
Interim Chief Financial Officer
97.00K
--
Dr. Nancy Chung-Welch, Ph.D.
Dr. Nancy Chung-Welch, Ph.D.
Independent Director
Independent Director
83.99K
+334.90%
Dr. Daniel E. (Dan) Handley, Ph.D.
Dr. Daniel E. (Dan) Handley, Ph.D.
Independent Director
Independent Director
81.70K
+380.07%
Dr. Veena Rao, Ph.D.
Dr. Veena Rao, Ph.D.
Independent Director
Independent Director
73.80K
+709.44%
Dr. Matthew J. Hawryluk, Ph.D.
Dr. Matthew J. Hawryluk, Ph.D.
Independent Director
Independent Director
--
--
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: qua, 17 de set
Atualizado em: qua, 17 de set
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Vennare (Raymond F)
1.15%
Blacher (Joshua)
0.85%
Nuzum (Charles Lee Sr)
0.83%
St Clair (Gregory Sr)
0.75%
Chung-Welch (Nancy)
0.73%
Outro
95.68%
Investidores
Investidores
Proporção
Vennare (Raymond F)
1.15%
Blacher (Joshua)
0.85%
Nuzum (Charles Lee Sr)
0.83%
St Clair (Gregory Sr)
0.75%
Chung-Welch (Nancy)
0.73%
Outro
95.68%
Tipos de investidores
Investidores
Proporção
Individual Investor
6.32%
Investment Advisor/Hedge Fund
0.67%
Investment Advisor
0.66%
Research Firm
0.15%
Endowment Fund
0.09%
Hedge Fund
0.01%
Outro
92.09%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
44
299.51K
2.93%
-288.64K
2025Q1
50
299.35K
3.35%
-293.31K
2024Q4
56
353.94K
4.97%
-213.96K
2024Q3
54
322.08K
5.97%
-246.26K
2024Q2
57
408.73K
8.00%
-114.07K
2024Q1
66
484.20K
11.91%
-86.59K
2023Q4
66
502.45K
12.36%
-67.11K
2023Q3
69
499.46K
12.41%
-50.95K
2023Q2
67
353.15K
8.84%
-144.84K
2023Q1
72
429.97K
10.87%
-298.57K
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Vennare (Raymond F)
7.12K
0.08%
--
--
Mar 20, 2025
Nuzum (Charles Lee Sr)
29.91K
0.33%
+2.01K
+7.22%
Mar 20, 2025
St Clair (Gregory Sr)
21.20K
0.24%
+1.33K
+6.70%
Mar 20, 2025
Chung-Welch (Nancy)
19.31K
0.22%
+2.01K
+11.64%
Mar 20, 2025
Handley (Daniel E)
17.02K
0.19%
+1.64K
+10.69%
Mar 20, 2025
Hawryluk (Matthew)
9.49K
0.11%
--
--
Mar 20, 2025
Rao (Veena)
9.12K
0.1%
--
--
Mar 20, 2025
The Vanguard Group, Inc.
71.31K
0.8%
--
--
Mar 31, 2025
Geode Capital Management, L.L.C.
62.93K
0.7%
+11.72K
+22.90%
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 6 de set
Atualizado em: sáb, 6 de set
Nome
Proporção
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
Proporção0%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Apr 20, 2023
Merger
20→1
Apr 20, 2023
Merger
20→1
Apr 20, 2023
Merger
20→1
Apr 20, 2023
Merger
20→1
Data
Tipo
Proporção
Apr 20, 2023
Merger
20→1
Apr 20, 2023
Merger
20→1
Apr 20, 2023
Merger
20→1
Apr 20, 2023
Merger
20→1
